Mucus-Busting asthma trial fizzles out
NCT ID NCT03822637
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small study tested whether adding n-acetylcysteine (NAC) to albuterol could improve lung function and reduce mucus plugs in people with moderate-to-severe asthma. Only 4 participants were enrolled before the trial was terminated early. The crossover design gave each person two weeks of NAC plus albuterol and two weeks of placebo plus albuterol, but the tiny size means no firm conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- n-acetylcysteine (NAC) plus albuterol
- What this could lead to
- If it works, this could point toward a way to clear mucus plugs in the airways and improve breathing for people with moderate-to-severe asthma.
- What could go wrong
- The trial was terminated early and enrolled only 4 people, so results are very limited. It is unclear if NAC provides any real benefit over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
4 people
The number who actually took part.
- Started
-
Feb 2019
- Finished
-
Feb 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female between the ages of 18 and 80 years of age at Visit 1 2. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. 3. Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria 4. Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine provocative concentration that results in a 20% fall in FEV1(PC20) ≤ 16 mg/mL) 5. Clinical history of asthma per patient report or medical record 6. Pre-bronchodilator FEV1 \> 35% predicted 7. Post-bronchodilator FEV1 \> 40% but \< 90% predicted 8. Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater 9. CT mucus score ≥ 5 10. Ability to tolerate study drug reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1 Exclusion Criteria: 1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data 3. Smoking of tobacco or other recreational inhalants in last year and/or \>10 pack-year smoking history 4. Adherence to study drug ≤ 70% after first treatment period 5. Current participation in an investigational drug trial 6. Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways 7. Unwillingness to follow study procedures 8. History of allergy or intolerance to study drug 9. Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSF Airway Clinical Research Center
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breath test cut asthma Flare-Ups?
- Breathing tests face off: can extra lung measurements improve asthma diagnosis?
- The carbon label on your inhaler: can it sway a Doctor's choice?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a digital program help teens with chronic illnesses move to adult care?
- Why do some kids catch every cold? a 1,200-Child study hunts for immune clues